GLP-1 receptor agonist use for diabetes or obesity was associated with significantly lower overall mortality and fewer major cardiovascular events in patients with hidradenitis suppurativa.The analysis showed evidence of broad systemic benefits beyond cardiometabolic risk reduction, including reduced risk for sepsis, cellulitis, and lymphedema.Prospective studies are required to confirm these observational findings.
Patients with hidradenitis suppurative (HS) and a history of GLP-1 receptor agonist use for diabetes or obesity had significantly lower rates of multiple cardiovascular events and mortality, a large retrospective cohort study showed.
During 2 years of follow-up, patients with at least two prescriptions for GLP-1 agonists had a significantly lower overall mortality and rate of major adverse cardiovascular events. Statistically significant risk reductions were seen after 1 and 2 years of follow-up for cardiovascular procedures, ischemic heart disease, and heart failure, as well as the inflammation-associated outcomes of sepsis, lymphedema, and cellulitis.
The findings add to accumulating evidence that GLP-1 agonists' therapeutic potential extends beyond glucose regulation, the initial goal of the drugs' development, reported Jacek C. Szepietowski, MD, PhD, of Wroclaw University of Science and Technology in Poland, and colleagues in JAMA Dermatology.
